Palvella Therapeutics (PVLA) Operating Expenses (2013 - 2026)

Palvella Therapeutics (PVLA) has 14 years of Operating Expenses data on file, last reported at $14.9 million in Q1 2026.

• On a quarterly basis, Operating Expenses rose 88.73% year-over-year to $14.9 million in Q1 2026; TTM through Mar 2026 was $45.6 million, a 125.6% increase from a year earlier, with the FY2025 full-year figure at $38.6 million, up 173.87% from the prior year.
• Operating Expenses for Q1 2026 stood at $14.9 million, up from $11.3 million in the prior quarter.
• Over the last five years, Operating Expenses for PVLA reached as high as $31.3 million in Q3 2023 and fell as low as -$54.9 million in Q4 2023.
• Historically, Operating Expenses has averaged $8.8 million across 5 years, with a median of $11.3 million in 2025.
• Across the five-year window, Operating Expenses sank 416.14% in 2023 and soared 347.47% in 2025, its largest moves.
• Year by year, Operating Expenses stood at $17.4 million in 2022, then sank by 416.14% to -$54.9 million in 2023, then soared by 107.95% to $4.4 million in 2024, then soared by 158.91% to $11.3 million in 2025, then surged by 31.41% to $14.9 million in 2026.
• Per Business Quant data, the three most recent Operating Expenses figures were $14.9 million in Q1 2026, $11.3 million in Q4 2025, and $10.2 million in Q3 2025.